What is it that you've discovered or that you're doing differently to some of those others?

Yeah, that's a good question.

When you look at the clinical pipeline in Parkinson, many of those programs are focused on one pathway or even maybe one aspect of a pathway in a cell.

And I think the last few years, maybe not only for Parkinson's, but for neurodegeneration in general, has been quite humbling, where a few of those very prominent programs have failed to meet their endpoints.

And I think what we do fundamentally different is that the mechanism we target is basically designed to restore the cell's own housekeeping machinery.

So it does this in two mechanisms.

It improves the lysosomal system and the ability of a cell to clear waste products.

And so where are you at currently with clinical trials? And could you share some of the information that you've gathered from those?